Orexin loss in Huntington's disease

Area of Science:

• Neuroscience
• Genetics
• Neuropathology

Background:

• Huntington's disease (HD) is a neurodegenerative disorder linked to CAG repeat expansion in the huntingtin gene.
• Mutant huntingtin causes neuronal death, but neuronal loss is minimal in the R6/2 mouse model.
• Orexin system dysfunction is implicated in sleep disorders and neurodegeneration.

Purpose of the Study:

• To investigate the impact of Huntington's disease on orexin neurons in the R6/2 mouse model.
• To determine if orexin neuron loss occurs in Huntington's disease patients.
• To explore the potential of orexin as a biomarker for HD-related neurodegeneration.

Main Methods:

• Utilized the R6/2 mouse model of Huntington's disease.
• Examined orexin neuron morphology and count in the lateral hypothalamus.
• Measured orexin levels in cerebrospinal fluid.
• Compared findings in R6/2 mice with wild-type littermates and Huntington's disease patients.

Main Results:

• Observed significant atrophy and loss of orexin neurons in the lateral hypothalamus of R6/2 mice.
• Confirmed similar atrophy and loss of orexin neurons in Huntington's disease patients.
• R6/2 mice exhibited narcoleptic behaviors, consistent with impaired orexin function.
• Orexin neuron numbers and cerebrospinal fluid orexin levels were reduced by 72% in end-stage R6/2 mice.

Conclusions:

• Orexin neuron loss is a novel and significant pathology in Huntington's disease.
• Orexin deficiency contributes to narcolepsy observed in HD models and patients.
• Orexin levels may serve as a valuable biomarker for tracking neurodegeneration in Huntington's disease.